The 2016 WHOClassification of
tumors of Urothelial tract .
15.
Papillary Urothelial
Carcinoma
Macroscopic Appearances:
Some are barely visible small papillary
excrescences whereas others are huge
masses of confluent papillary tissue that
may have a “cauliflower-like” appearance
almost filling the bladder lumen.
They are typically soft, delicate, and friable.
16.
Microscopic findings
Complexbranching pattern
The papillae are usually covered by
more than seven layers of cells.
Cytologic atypia present.
Atypical mitosis may b present
17.
Papillary carcinomasare graded by
using cytologic and architectural criteria,
and this has major prognostic
significance.
A system of three categories is widely
recommended and generally used.
PAPILLARY UROTHELIAL
NEOPLASM OFLOW MALIGNANT
POTENTIAL
Papillae usually covered by a thickened
epithelium.
The cells are normally oriented and
show mild degrees of nuclear
enlargement and hyperchromasia.
Mitoses are infrequent and basally
located if present.
Apoptotic bodies rarely seen.
Invasion is infrequent.
20.
LOW-GRADE PAPILLARY
CARCINOMA
Branchingpapillae, fused and delicate.
Predominantly ordered, yet minimal
crowding and minimal loss of polarity;
any thickness; cohesive.
Enlarged round to oval nucleus with
variation in size and shape.
Mitosis - occasional, at any level.
21.
HIGH-GRADE PAPILLARY
CARCINOMA
Papillaeare fused, branching.
Predominantly disordered with frequent
loss of polarity; any thickness; often
discohesive.
Nucleus - enlarged , hyperchromatic
with moderate–marked pleomorphism.
Multiple prominent nucleoli .
Mitosis- Usually frequent, at any level with
abnormal mitotic forms.
23.
Local spread andmetastases
Assessment of invasion in cases of papillary
carcinoma may be difficult.
Tangential sectioning of the bases of papillae
may simulate invasion by giving the
appearance of detached nests of cells in the
lamina propria.
Most crucial to prognosis is the presence or
absence of invasion of the muscularis propria.
24.
Invasive bladdercarcinomas (especially
high-grade tumors) are associated with
zones of atypical proliferation,
carcinoma in situ, and early invasive
carcinomas in areas remote from the
main tumor mass.
25.
Bladder carcinomamay extend into the
neck of the bladder, urethra, prostatic
ducts, and seminal vesicle;
more commonly than to the ureters.
Lymph node metastases in the pelvic
chains are found in 25% of the invasive
tumors.
Distant metastases seen in lungs, liver,
bone, and central nervous system.
26.
To differentiate betweenhigh-grade
malignant tumor for which the differential
diagnosis is between urothelial and
prostatic carcinoma:
CK34ßE12, CK7, P53 = positive in
urothelial carcinoma.
PSA, PSAP, and Leu7(CD57) = positive in
prostatic carcinoma.
This panel of six markers is essential to
differentiate.
27.
The selection ofthe antibody panel to use
in a given case depends to a large extent
on the differential diagnosis being
considered
1.Urothelial carcinoma with inverted
growth pattern versus inverted
papilloma:
Ki-67,
P53 and
CK20
(all of them usually positive in the former)
28.
2. High-grade urothelialcarcinoma versus
poorly differentiated prostatic
adenocarcinoma:
CK34ßE12 and p63 (positive in the
former), and
PSA (positive in the latter)
29.
3. Metastatic micropapillaryurothelial
carcinoma of prostate versus
micropapillary carcinoma of other sites:
uroplakin,
CK20,
TTF-1, and
hormone receptors
30.
The pathologyreport of a bladder biopsy that
contains a tumor should include the following
information:
1 Grade
2 Configuration (papillary or solid)
3 Depth of penetration
4 Presence of muscle
5 Lymphatic invasion
6 Blood vessel invasion
7 Changes in adjacent mucosa if present